108
Registered trials
40
Recruiting
50
Completed trials
75
Sponsors
23
Countries
Phase III:
27
Phase II/III:
6
Phase II:
36
Phase I/II:
7
Phase III/IV:
3
Phase IV:
21
Phase I:
2
Phase I (Other):
1
Phase I (FiH):
4
Other:
1
Oversight events:
3 serious breaches
31 temporary halts
2 urgent safety measures
3 unexpected events
3 corrective measures
across 15 trials
View oversight register →
Indications tested
Multiple sclerosis
5
Relapsing-remitting multiple sclerosis
3
Multiple sclerosis relapse
2
Relapsing multiple sclerosis
2
Diffuse large B-cell lymphoma recurrent
2
Follicular lymphoma
1
Metastatic malignant melanoma
1
Myasthenia gravis
1
Primary progressive multiple sclerosis
1
Amyotrophic lateral sclerosis
1
Coronary artery disease
1
Endometriosis
1
Sponsors using this IMP
F. Hoffmann-La Roche AG
6
Regeneron Pharmaceuticals Inc.
5
Centre Hospitalier Universitaire Amiens Picardie
3
Centre Hospitalier Universitaire De Nantes
3
Aarhus Universitet
2
Allogene Therapeutics Inc.
2
Assistance Publique Hopitaux De Paris
2
Celltrion Inc.
2
Centre hospitalier universitaire de Liege
2
Charite Universitaetsmedizin Berlin KöR
2
Emn Trial Office S.r.l. Impresa Sociale
2
European Myeloma Network B.V.
2
All trials — page 5
108 total-
CHRONDI Ended
Showing 97–108 of 108 trials